Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial

J P Mohr, Michael K Parides, Christian Stapf, Ellen Moquete, Claudia S Moy, Jessica R Overbey, Rustam Al-Shahi Salman, Eric Vicaut, William L Young, Emmanuel Houdart, Charlotte Cordonnier, Marco A Stefani, Andreas Hartmann, Rüdiger von Kummer, Alessandra Biondi, Joachim Berkefeld, Catharina J M Klijn, Kirsty Harkness, Richard Libman, Xavier BarreauAlan J Moskowitz, for the international ARUBA investigators

Research output: Contribution to journalArticlepeer-review

Abstract

The clinical benefit of preventive eradication of unruptured brain arteriovenous malformations remains uncertain. A Randomised trial of Unruptured Brain Arteriovenous malformations (ARUBA) aims to compare the risk of death and symptomatic stroke in patients with an unruptured brain arteriovenous malformation who are allocated to either medical management alone or medical management with interventional therapy.
Original languageEnglish
JournalThe Lancet
DOIs
Publication statusPublished - 19 Nov 2013

Fingerprint Dive into the research topics of 'Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial'. Together they form a unique fingerprint.

Cite this